About · the publisher
About Legit CJC-1295
An independent editorial project that reads the published CJC-1295 literature straight — what the human pharmacokinetics and the regulators actually establish, with the gaps left visible.
What this site is
Legit CJC-1295 is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The "legit" in the name is editorial framing — a posture toward the literature, not a claim about services. It signals the site's purpose: to separate what the published research and the regulators actually establish from the marketing and forum claims that surround this compound. It is a position relative to the evidence, not an endorsement of the compound or an offer of anything for sale.
How we read the evidence
The site is organized by how well-established each claim is. Findings with human pharmacokinetic data are placed in front; mechanistic and animal work sits a step behind; the honest gaps and the regulatory boundaries are placed furthest back and are never hidden. That structure is deliberate, because the most common failure in CJC-1295 coverage is presenting thin or absent evidence with the same confidence as the human PK studies.
Every quantitative claim on this site cites a study, and every citation resolves to a PubMed or DOI link on the references page. Where the literature is limited — and for CJC-1295, the human literature is limited to a handful of early pharmacokinetic studies — the digest says so plainly. We do not extend the data past what it measured, and we surface the DAC versus no-DAC distinction first because it is the fact most often collapsed.
Why a dedicated CJC-1295 digest
CJC-1295 is unusually prone to misdescription. Its two forms have opposite pharmacokinetics yet share a name; its human evidence is a handful of early studies routinely cited as if it were a mature clinical record; and its regulatory status is frequently softened in promotional writing. A compound described this inconsistently benefits from a single page that reads the primary sources straight.
That is the whole remit. We do not have a position on whether anyone should be interested in CJC-1295 — only on what the literature and the regulators actually say when read carefully. The DAC versus no-DAC distinction, the 5.8-to-8.1-day half-life of the long-acting form, the absence of long-term human safety data, and the 2024 FDA decision not to recommend it for the 503A list are all part of the same honest summary, and none of them is more convenient than the others.
What we do not do
We do not provide human dosing, treatment plans, or consultation. We do not sell, source, or recommend suppliers of CJC-1295. We do not present community protocols as evidence. CJC-1295 is not approved for human use, and nothing here should be read as guidance to use it.
This is a research digest: an instrument of record for a compound that is frequently and inconsistently described elsewhere. The references are the authority; this site is the reading.